© 2014 - 2022
ReMedDev® is a TM of
Vermilion Life Sciences Ltd
In conjunction with ABPI a Reengineering Medicines Development discussion document was authored. Please click the first image to download the document.
A stakeholder roundtable to discuss and define partnership possibilities was jointly hosted with ABPI on 4th March 2015. Please click the second image to download the summary output report.
The principles of ReMedDev® are visible within the Accelerated Access Review final report
Articles in Scrip and KPMG's Focus on Life Sciences (Page 14) are available via the images below